# EDGAR Filing Document

**Accession Number:** 0001817229
**File Stem:** 0000000000-26-001167
**Filing Date:** 2026-1
**Character Count:** 2213
**Document Hash:** 306c18e4aedb6743939148fb554853ce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-001167.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0000000000-26-001167

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260130

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vor Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001817229
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811591163
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-293052

**BUSINESS ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-655-6580

**MAIL ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-26-029364

## Text-Extract

```

                                                           January 30, 2026

Jean-Paul Kress, M.D.
President, Chief Executive Officer and Chairman of the Board
Vor Biopharma Inc.
500 Boylston Street, Suite 1350
Boston, MA 02116

       Re: Vor Biopharma Inc.
           Registration Statement on Form S-3
           Filed January 29, 2026
           File No. 333-293052
Dear Jean-Paul Kress M.D.:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Daniel Crawford at 202-551-7767 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Div Gupta, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._